Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy Paul

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Physical Review Letters|May 14, 2021
Testing Quantum Electrodynamics with Exotic AtomsNancy Paul, Guojie Bian, Toshiyuki Azuma, et al.
Journal of Medical Economics|July 19, 2023
Early access for innovative oncology medicines: a different story in each nationTara Cowling, Ransi Nayakarathna, Allison L Wills, et al.
Journal of Palliative Care|February 6, 2010
Satisfaction with end-of-life care: a longitudinal study of patients and their family caregivers in the last months of lifeDaren K Heyland, Christopher Frank, Joan Tranmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Factors affecting workload of cancer clinical trials: results of a multicenter study of the National Cancer Institute of Canada Clinical Trials GroupKathyrn Roche, Nancy Paul, Bobbi Smuck, et al.
Journal of Comparative Effectiveness Research|April 24, 2025
Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experienceChakrapani Balijepalli, Lakshmi Gullapalli, Swati Prasad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2005
Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5Mark N Levine, Kathleen I Pritchard, Vivien H C Bramwell, et al.
Cancers|September 28, 2024
The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus ObinutuzumabKimberly Guinan, Karine Mathurin, Jean Lachaine, et al.
Journal of Comparative Effectiveness Research|April 20, 2026
Health care resource use in the management of patients with relapsed/refractory diffuse large B-cell lymphoma - Canadian perspectiveKimberly Guinan, Mathieu Pelletier, Monika Ham, et al.
Pharmacoeconomics - Open|November 7, 2025
Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility AnalysisGijs van de Wetering, Carolyn Owen, Versha Banerji, et al.
Cancer|September 24, 2004
Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)Michael Crump, Tara Baetz, Stephen Couban, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Physical Review Letters|May 14, 2021
Testing Quantum Electrodynamics with Exotic AtomsNancy Paul, Guojie Bian, Toshiyuki Azuma, et al.
Journal of Medical Economics|July 19, 2023
Early access for innovative oncology medicines: a different story in each nationTara Cowling, Ransi Nayakarathna, Allison L Wills, et al.
Journal of Palliative Care|February 6, 2010
Satisfaction with end-of-life care: a longitudinal study of patients and their family caregivers in the last months of lifeDaren K Heyland, Christopher Frank, Joan Tranmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2002
Factors affecting workload of cancer clinical trials: results of a multicenter study of the National Cancer Institute of Canada Clinical Trials GroupKathyrn Roche, Nancy Paul, Bobbi Smuck, et al.
Journal of Comparative Effectiveness Research|April 24, 2025
Time-limited reimbursement and Temporary Access Process for early access to oncology treatments in Canada: a perspective based on the epcoritamab experienceChakrapani Balijepalli, Lakshmi Gullapalli, Swati Prasad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2005
Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5Mark N Levine, Kathleen I Pritchard, Vivien H C Bramwell, et al.
Cancers|September 28, 2024
The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus ObinutuzumabKimberly Guinan, Karine Mathurin, Jean Lachaine, et al.
Journal of Comparative Effectiveness Research|April 20, 2026
Health care resource use in the management of patients with relapsed/refractory diffuse large B-cell lymphoma - Canadian perspectiveKimberly Guinan, Mathieu Pelletier, Monika Ham, et al.
Pharmacoeconomics - Open|November 7, 2025
Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility AnalysisGijs van de Wetering, Carolyn Owen, Versha Banerji, et al.
Cancer|September 24, 2004
Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)Michael Crump, Tara Baetz, Stephen Couban, et al.
Pageof 2